266 related articles for article (PubMed ID: 21150717)
1. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
Kaida M; Morita-Hoshi Y; Soeda A; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Takaue Y; Heike Y
J Immunother; 2011 Jan; 34(1):92-9. PubMed ID: 21150717
[TBL] [Abstract][Full Text] [Related]
2. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial).
Okusaka T; Ueno M; Sato T; Heike Y
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):314-8. PubMed ID: 22273718
[TBL] [Abstract][Full Text] [Related]
3. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.
Nishida S; Ishikawa T; Egawa S; Koido S; Yanagimoto H; Ishii J; Kanno Y; Kokura S; Yasuda H; Oba MS; Sato M; Morimoto S; Fujiki F; Eguchi H; Nagano H; Kumanogoh A; Unno M; Kon M; Shimada H; Ito K; Homma S; Oka Y; Morita S; Sugiyama H
Cancer Immunol Res; 2018 Mar; 6(3):320-331. PubMed ID: 29358173
[TBL] [Abstract][Full Text] [Related]
4. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
Nishida S; Koido S; Takeda Y; Homma S; Komita H; Takahara A; Morita S; Ito T; Morimoto S; Hara K; Tsuboi A; Oka Y; Yanagisawa S; Toyama Y; Ikegami M; Kitagawa T; Eguchi H; Wada H; Nagano H; Nakata J; Nakae Y; Hosen N; Oji Y; Tanaka T; Kawase I; Kumanogoh A; Sakamoto J; Doki Y; Mori M; Ohkusa T; Tajiri H; Sugiyama H
J Immunother; 2014; 37(2):105-14. PubMed ID: 24509173
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.
Suzuki N; Hazama S; Ueno T; Matsui H; Shindo Y; Iida M; Yoshimura K; Yoshino S; Takeda K; Oka M
J Immunother; 2014 Jan; 37(1):36-42. PubMed ID: 24316554
[TBL] [Abstract][Full Text] [Related]
6. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.
Yanagimoto H; Shiomi H; Satoi S; Mine T; Toyokawa H; Yamamoto T; Tani T; Yamada A; Kwon AH; Komatsu N; Itoh K; Noguchi M
Oncol Rep; 2010 Sep; 24(3):795-801. PubMed ID: 20664989
[TBL] [Abstract][Full Text] [Related]
8. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
9. Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.
Soeda A; Morita-Hoshi Y; Kaida M; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Heike Y
Jpn J Clin Oncol; 2010 Dec; 40(12):1184-8. PubMed ID: 20656693
[TBL] [Abstract][Full Text] [Related]
10. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
Yanagimoto H; Mine T; Yamamoto K; Satoi S; Terakawa N; Takahashi K; Nakahara K; Honma S; Tanaka M; Mizoguchi J; Yamada A; Oka M; Kamiyama Y; Itoh K; Takai S
Cancer Sci; 2007 Apr; 98(4):605-11. PubMed ID: 17309598
[TBL] [Abstract][Full Text] [Related]
11. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Dalgleish AG; Stebbing J; Adamson DJ; Arif SS; Bidoli P; Chang D; Cheeseman S; Diaz-Beveridge R; Fernandez-Martos C; Glynne-Jones R; Granetto C; Massuti B; McAdam K; McDermott R; MartÃn AJ; Papamichael D; Pazo-Cid R; Vieitez JM; Zaniboni A; Carroll KJ; Wagle S; Gaya A; Mudan SS
Br J Cancer; 2016 Sep; 115(7):789-96. PubMed ID: 27599039
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.
Lin LL; Picus J; Drebin JA; Linehan DC; Solis J; Strasberg SM; Tan B; Thorstad WL; Myerson R
Am J Clin Oncol; 2005 Jun; 28(3):234-41. PubMed ID: 15923794
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.
Miyazawa M; Ohsawa R; Tsunoda T; Hirono S; Kawai M; Tani M; Nakamura Y; Yamaue H
Cancer Sci; 2010 Feb; 101(2):433-9. PubMed ID: 19930156
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer.
Matsuyama M; Ishii H; Furuse J; Ohkawa S; Maguchi H; Mizuno N; Yamaguchi T; Ioka T; Ajiki T; Ikeda M; Hakamada K; Yamamoto M; Yamaue H; Eguchi K; Ichikawa W; Miyazaki M; Ohashi Y; Sasaki Y
Invest New Drugs; 2015 Apr; 33(2):490-5. PubMed ID: 25502982
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
